Shots:

• The approval follows P-III ORIENT-11 study assessing Tyvyt (sintilimab) vs PBO + Almita (pemetrexed) and platinum CT in 397 participants in a ratio (2:1) as 1L therapy for advanced or recurrent nsqNSCLC
• Results: Improvement in PFS- as assessed by IRC; mPFS (8.9 vs 5.0mos.); safety profile is consistent with previously reported studies with no new safety signals. At updated analysis after extended follow up- mOS (not reached vs 16.0 mos.)
• Sintilimab is an innovative PD-1 inhibitor- jointly developed by Eli Lilly and Innovent. The approval marks the second indication for sintilimab in China

 ­ Ref: PRNewswire | Image: Innovent